Mylan intros generic Clolar for injection

PITTSBURGH — Mylan has introduced its generic of Clolar (clofarabine 1 mg/ml) injection. The drug is indicated to treat patients ages 1 year to 21 years with relapsed or refractory acute lymphoblastic leukemia after at least two prior treatment regimens.

The latest launch adds to Mylan’s oncology portfolio, which it said contains more than 40 products. Mylan’s Clolar generic will be available in single-dose vials.

According to data from IQVIA (formerly QuintilesIMS), the drug had U.S. sales of $53 million for the 12 months ended Sept. 30.